Efficacy and Safety of Finasteride Monotherapy in Patients with Benign Prostatic Hyperplasia: A Critical Review of the Literature

January 2020 in “ Archivio Italiano di Urologia e Andrologia ”

Gian Maria Busetto, Francesco Del Giudice, Daniele D’Agostino, Daniele Romagnoli, Andrea Minervini, Bernardo Rocco, Alessandro Antonelli, Antonio Celia, Riccardo Schiavina, Luca Cindolo, Benjamin I. Chung, Jae Heon Kim, Martina Maggi, Alessandro Sciarra, Ettore De Berardinis, Angelo Porreca

finasteride 5 alpha-reductase inhibitor benign prostatic hyperplasia BPH International Prostate Symptom Score IPSS maximum urinary flow rate Qmax alpha blockers Propecia

Studysummary This review found that finasteride monotherapy for managing LUTS/BPH significantly reduced prostate volume and improved symptoms, with sexual dysfunctions reported as notable side effects compared to placebo, but emphasizes the need for more comprehensive studies.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on pagepressjournals.org →

Discuss this study in the Community →

Research cited in this study

10 / 10 results

research Risk of Depression After 5 Alpha Reductase Inhibitor Medication: Meta-Analysis

4 citations , May 2019 in “The World Journal of Men's Health”

This study found no significant increase in depression risk associated with taking five-alpha reductase inhibitors for benign prostatic hyperplasia or alopecia, although further studies are needed to confirm these findings.

research Efficacy and Safety of 5 Alpha-Reductase Inhibitor Monotherapy in Patients with Benign Prostatic Hyperplasia: A Meta-Analysis

19 citations , October 2018 in “PLOS ONE”

This study found that 5-alpha-reductase inhibitor monotherapy for symptomatic benign prostatic hyperplasia showed some clinical benefit over placebo but was linked to a higher incidence of sexual side effects.

Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-Analysis

research Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-Analysis

15 citations , January 2018 in “Acta dermato-venereologica”

This meta-analysis found that treating male androgenetic alopecia with 5α-reductase inhibitors increases the risk of sexual dysfunction, with a statistically significant risk for finasteride but not for dutasteride.

research Current Pharmacological Treatment for Male LUTS Due to BPH: Dutasteride or Finasteride?

21 citations , October 2015 in “Current Drug Targets”

This review discusses the comparative efficacy of dutasteride and finasteride for benign prostatic hyperplasia, reporting that while symptom improvements are similar, dutasteride may reduce prostate surgery risk and acute urinary retention more effectively.

research Depressive Symptoms and Suicidal Thoughts Among Former Users of Finasteride With Persistent Sexual Side Effects

134 citations , August 2012 in “The Journal of Clinical Psychiatry”

This study found that former finasteride users with persistent sexual side effects reported significantly higher rates of depressive symptoms and suicidal thoughts compared to controls.

research Persistent Sexual Side Effects of Finasteride: Could They Be Permanent?

112 citations , July 2012 in “The Journal of Sexual Medicine”

In this study, 96% of men with persistent sexual side effects from finasteride reported continued dysfunction after discontinuation, suggesting these effects may endure long-term.

research Promising Therapies for Treating and Preventing Androgenic Alopecia

36 citations , June 2012 in “PubMed”

This review discusses various treatments for androgenetic alopecia, including minoxidil, finasteride, dutasteride, ketoconazole, and experimental options, but reports limited clinical trial evidence for efficacy.

research The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia

1707 citations , December 2003 in “The New England Journal of Medicine”

Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.

research Effects of Finasteride on Vascular Endothelial Growth Factor

35 citations , January 2002 in “Scandinavian Journal of Urology and Nephrology”

This study found that finasteride treatment decreased VEGF expression in the prostate tissue of patients with benign prostatic hyperplasia, although it did not affect vascular density or serum VEGF levels.

research The Effect of Finasteride in Men with Benign Prostatic Hyperplasia

1040 citations , October 1992 in “The New England Journal of Medicine”

In this study, 5 mg of finasteride per day significantly improved urinary symptoms and reduced prostate volume in men with benign prostatic hyperplasia, but increased the risk of sexual dysfunction.